http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html si-local-file:///var/storage/secattach/20260603/26599991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html Wed, 03 Jun 2026 16:57:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html si-local-file:///var/storage/secattach/20260603/26599991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Jun+03/26599991.html Wed, 03 Jun 2026 16:57:00 -0400 O.58280676 SXTP http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has enrolled the first patient of the 2026 tick season in its clinical trial evaluating tafenoquine for treating babesiosis in hospitalized patients, according to a company statement.</p><p>The randomized, double-blind, placebo-controlled trial (NCT06207370) is being conducted at five clinical sites in the northeastern United States. The study will enroll at least 24 patients before conducting an interim analysis, with two primary endpoints: time to clinical symptom resolution and parasite clearance.</p><p>Enrollment is proceeding approximately one month ahead of schedule, which could allow the company to reach minimum enrollment for interim analysis as early as July 2026. http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html Tue, 26 May 2026 08:03:23 -0400 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has enrolled the first patient of the 2026 tick season in its clinical trial evaluating tafenoquine for treating babesiosis in hospitalized patients, according to a company statement.</p><p>The randomized, double-blind, placebo-controlled trial (NCT06207370) is being conducted at five clinical sites in the northeastern United States. The study will enroll at least 24 patients before conducting an interim analysis, with two primary endpoints: time to clinical symptom resolution and parasite clearance.</p><p>Enrollment is proceeding approximately one month ahead of schedule, which could allow the company to reach minimum enrollment for interim analysis as early as July 2026. http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html Tue, 26 May 2026 08:03:23 -0400 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+60+Degrees+Pharmaceuticals+Inc+%28SXTP%29+to+Neutral/26527001.html <p>H.C. Wainwright analyst Ed White downgraded 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) from Buy to Neutral.</p><p>For an analyst ratings summary and ratings history on 60 Degrees Pharmaceuticals Inc <a href="http://www.streetinsider.com/rating_history.php?q=SXTP">click here</a>. For more ratings news on 60 Degrees Pharmaceuticals Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=SXTP&amp;type=analyst">click here</a>.</p><p>Shares of 60 Degrees Pharmaceuticals Inc closed at $1.41 yesterday.</p> http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+60+Degrees+Pharmaceuticals+Inc+%28SXTP%29+to+Neutral/26527001.html Wed, 20 May 2026 12:19:06 -0400 SXTP http://www.streetinsider.com/SEC+Filings/Form++3++++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13++Filed+by%3A+Francois+Eric/26523031.html si-local-file:///var/storage/secattach/20260519/26523031.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13++Filed+by%3A+Francois+Eric/26523031.html Tue, 19 May 2026 18:14:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++3++++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13++Filed+by%3A+Francois+Eric/26523031.html si-local-file:///var/storage/secattach/20260519/26523031.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13++Filed+by%3A+Francois+Eric/26523031.html Tue, 19 May 2026 18:14:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13/26514466.html si-local-file:///var/storage/secattach/20260518/26514466.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13/26514466.html Mon, 18 May 2026 16:33:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13/26514466.html si-local-file:///var/storage/secattach/20260518/26514466.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+May+13/26514466.html Mon, 18 May 2026 16:33:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+Knight+Therapeutics+Inc./26504894.html si-local-file:///var/storage/secattach/20260515/26504894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+Knight+Therapeutics+Inc./26504894.html Fri, 15 May 2026 16:05:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+Knight+Therapeutics+Inc./26504894.html si-local-file:///var/storage/secattach/20260515/26504894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+Knight+Therapeutics+Inc./26504894.html Fri, 15 May 2026 16:05:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502729.html si-local-file:///var/storage/secattach/20260515/26502729.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502729.html Fri, 15 May 2026 12:22:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502729.html si-local-file:///var/storage/secattach/20260515/26502729.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++60+DEGREES+PHARMACEUTICA+++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502729.html Fri, 15 May 2026 12:22:00 -0400 O.58280676 SXTP http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+First+Quarter+2026+Results/26500228.html <p>WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_Noq8YX96X06EtgKJluEA98SmKKyUxRemC52f5HUbriF73ZT1XV4W1gKlMmkQp7vRUekQaHuxtL4j8HPSCanHcFS1FTI8M-ZR5Wlnxz5YmLLjLzLKSrUmFROUIgGg2KwWb1i0YH_QrzGr1R_qduy_A==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc. </a>(NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uVBM0JZkd4s6-tAK20jOHrUucbOC30sod5IuuHXFOHJMRQbqq9scmcjAtmlarTlhl9-0kDyvoBePvFlpxDj4Ey6ueGLFo4G-t1HND-2rM2RI1_t53_1-OadzJfNVOe-gtgr-WE7Jz0Pa251c0ojdgw==" rel="nofollow" target="_blank">SXTP</a>; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026.</p> <p>Financial Highlights for the Quarter Ended March 31, 2026:</p> <ul type="disc"><li style="margin-bottom:8pt;">Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.</li><li style="margin-bottom:8pt;">The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+First+Quarter+2026+Results/26500228.html Fri, 15 May 2026 08:42:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+First+Quarter+2026+Results/26500228.html <p>WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_Noq8YX96X06EtgKJluEA98SmKKyUxRemC52f5HUbriF73ZT1XV4W1gKlMmkQp7vRUekQaHuxtL4j8HPSCanHcFS1FTI8M-ZR5Wlnxz5YmLLjLzLKSrUmFROUIgGg2KwWb1i0YH_QrzGr1R_qduy_A==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc. </a>(NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uVBM0JZkd4s6-tAK20jOHrUucbOC30sod5IuuHXFOHJMRQbqq9scmcjAtmlarTlhl9-0kDyvoBePvFlpxDj4Ey6ueGLFo4G-t1HND-2rM2RI1_t53_1-OadzJfNVOe-gtgr-WE7Jz0Pa251c0ojdgw==" rel="nofollow" target="_blank">SXTP</a>; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026.</p> <p>Financial Highlights for the Quarter Ended March 31, 2026:</p> <ul type="disc"><li style="margin-bottom:8pt;">Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.</li><li style="margin-bottom:8pt;">The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+First+Quarter+2026+Results/26500228.html Fri, 15 May 2026 08:42:00 -0400 O.58280676 SXTP SXTPW